drugset
drugset / Trial / NCT04766307

A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

NCT04766307 ↗

Phase 4 Unknown 1100 enrolled Beijing Chest Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.

Timeline

Start
2016-07-20
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic 500000 iu Subcutaneous

Indications

pulmonary tuberculosis